Geoff Daniels
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Geoff Daniels has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
C. Levene
Reference Laboratory for Immunohematology and Blood Groups, Blood Services Center, Magen David Adom, Israel
5 shared publicationsKirstin Finning
International Blood Group Reference Laboratory, Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, UK
5 shared publicationsP. Rouger
Centre national de Référence pour les Groupes sanguines, Paris, France
5 shared publicationsP. Sistonen
Finnish Red Cross Blood Transfusion Service, Helsinki, Finland
5 shared publicationsA. Fletcher
Growing Your Knowledge, Split Junction, NSW, Australia
4 shared publicationsC. Lomas‐Francis
New York Blood Center, New York, NY, USA
4 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 88 (2) , 477-478
Phase 1 Trial of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiation Therapy in Patients With Locoregionally Advanced Head-and-Neck Carcinoma
- 1 February 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 88 (2) , 477-478
Phase 1 Trial of Attenuated Vaccinia Virus (GL-ONC1) Delivered Intravenously With Concurrent Cisplatin and Radiation Therapy in Patients With Locoregionally Advanced Head-and-Neck Carcinoma
- Open Access
- 12 January 2009
- Published by Wiley in Vox Sanguinis
- Vol. 96 (2) , 153-156
International Society of Blood Transfusion Committee on Terminology for Red Blood Cell Surface Antigens: Macao report
- 12 January 2009
- Published by Wiley in Vox Sanguinis
- Vol. 96 (2) , 153-156
Open AccessInternational Society of Blood Transfusion Committee on Terminology for Red Blood Cell Surface Antigens: Macao report
- Open Access
- 10 December 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 29 (2) , 101-107
Noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects
Fetuses of women with alloantibodies to RhD (D) are at risk from hemolytic disease of the fetus and newborn, but only if the fetal red cells are D‐positive. In such pregnancies, it is beneficial to determine fetal D type, as this will affect the management of the pregnancy. It is possible to predict, with a high level of accuracy, fetal blood group phenotypes from genotyping tests on fetal DNA. The best source is the small quantity of fetal DNA in the blood of pregnant women, as this avoids the requirement for invasive procedures of amniocentesis or chorionic villus sampling (CVS). Many laboratories worldwide now provide noninvasive fetal D genotyping as a routine service for alloimmunized women, and some also test for c, E, C and K.In many countries, anti‐D immunoglobulin injections are offered to D‐negative pregnant women, to reduce the chances of prenatal immunization, even though up to 40% of these women will have a D‐negative fetus. High‐throughput, noninvasive fetal D genotyping technologies are being developed so that unnecessary treatment of pregnant women can be avoided. Trials suggest that fetal D typing of all D‐negative pregnant women is feasible and should become common practice in the near future. Copyright © 2008 John Wiley & Sons, Ltd.
- 10 December 2008
- Published by Wiley in Prenatal Diagnosis
- Vol. 29 (2) , 101-107
Open AccessNoninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects
Fetuses of women with alloantibodies to RhD (D) are at risk from hemolytic disease of the fetus and newborn, but only if the fetal red cells are D‐positive. In such pregnancies, it is beneficial to determine fetal D type, as this will affect the management of the pregnancy. It is possible to predict, with a high level of accuracy, fetal blood group phenotypes from genotyping tests on fetal DNA. The best source is the small quantity of fetal DNA in the blood of pregnant women, as this avoids the requirement for invasive procedures of amniocentesis or chorionic villus sampling (CVS). Many laboratories worldwide now provide noninvasive fetal D genotyping as a routine service for alloimmunized women, and some also test for c, E, C and K.In many countries, anti‐D immunoglobulin injections are offered to D‐negative pregnant women, to reduce the chances of prenatal immunization, even though up to 40% of these women will have a D‐negative fetus. High‐throughput, noninvasive fetal D genotyping technologies are being developed so that unnecessary treatment of pregnant women can be avoided. Trials suggest that fetal D typing of all D‐negative pregnant women is feasible and should become common practice in the near future. Copyright © 2008 John Wiley & Sons, Ltd.
Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study
Objectives To assess the feasibility of applying a high throughput method, with an automated robotic technique, for predicting fetal RhD phenotype from fetal DNA in the plasma of RhD negative pregnant women to avoid unnecessary treatment with anti-RhD immunoglobulin. Design Prospective comparison of fetal RHD genotype determined from fetal DNA in maternal plasma with the serologically determined fetal RhD phenotype from cord blood. Setting Antenatal clinics and antenatal testing laboratories in the Midlands and north of England and an international blood group reference laboratory. Participants Pregnant women of known gestation identified as RhD negative by an antenatal testing laboratory. Samples from 1997 women were taken at or before the 28 week antenatal visit. Main outcome measures Detection rate of fetal RhD from maternal plasma, error rate, false positive rate, and the odds of being affected given a positive result. Results Serologically determined RhD phenotypes were obtained from 1869 cord blood samples. In 95.7% (n=1788) the correct fetal RhD phenotype was predicted by the genotyping tests. In 3.4% (n=64) results were either unobtainable or inconclusive. A false positive result was obtained in 0.8% (14 samples), probably because of unexpressed or weakly expressed fetal RHD genes. In only three samples (0.2%) were false negative results obtained. If these results had been applied as a guide to treatment, only 2% of the women would have received anti-RhD unnecessarily, compared with 38% without the genotyping. Conclusions High throughput RHD genotyping of fetuses in all RhD negative women is feasible and would substantially reduce unnecessary administration of anti-RhD immunoglobulin to RhD negative pregnant women with an RhD negative fetus.
Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study
Objectives To assess the feasibility of applying a high throughput method, with an automated robotic technique, for predicting fetal RhD phenotype from fetal DNA in the plasma of RhD negative pregnant women to avoid unnecessary treatment with anti-RhD immunoglobulin. Design Prospective comparison of fetal RHD genotype determined from fetal DNA in maternal plasma with the serologically determined fetal RhD phenotype from cord blood. Setting Antenatal clinics and antenatal testing laboratories in the Midlands and north of England and an international blood group reference laboratory. Participants Pregnant women of known gestation identified as RhD negative by an antenatal testing laboratory. Samples from 1997 women were taken at or before the 28 week antenatal visit. Main outcome measures Detection rate of fetal RhD from maternal plasma, error rate, false positive rate, and the odds of being affected given a positive result. Results Serologically determined RhD phenotypes were obtained from 1869 cord blood samples. In 95.7% (n=1788) the correct fetal RhD phenotype was predicted by the genotyping tests. In 3.4% (n=64) results were either unobtainable or inconclusive. A false positive result was obtained in 0.8% (14 samples), probably because of unexpressed or weakly expressed fetal RHD genes. In only three samples (0.2%) were false negative results obtained. If these results had been applied as a guide to treatment, only 2% of the women would have received anti-RhD unnecessarily, compared with 38% without the genotyping. Conclusions High throughput RHD genotyping of fetuses in all RhD negative women is feasible and would substantially reduce unnecessary administration of anti-RhD immunoglobulin to RhD negative pregnant women with an RhD negative fetus.
- 1 December 2007
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 14 (6) , 568-571
Fetal RhD genotyping: A more efficient use of anti-D immunoglobulin
- 1 December 2007
- Published by Elsevier in Transfusion Clinique et Biologique
- Vol. 14 (6) , 568-571
Fetal RhD genotyping: A more efficient use of anti-D immunoglobulin
- Open Access
- 1 November 2007
- Published by Wiley in Vox Sanguinis
- Vol. 93 (4) , 331-340
Functions of red cell surface proteins
The external membrane of the red cell contains numerous proteins that either cross the lipid bilayer one or more times or are anchored to it through a lipid tail. Many of these proteins express blood group activity. The functions of some of these proteins are known; in others their function can only be surmised from the protein structure or from limited experimental evidence. They are loosely divided into four categories based on their functions: membrane transporters; adhesion molecules and receptors; enzymes; and structural proteins that link the membrane with the membrane skeleton. Some of the proteins carry out more than one of these functions. Some proteins may complete their major functions during erythropoiesis or may only be important under adverse physiological conditions. Furthermore, some might be evolutionary relics and may no longer have significant functions. Polymorphisms or rare changes in red cell surface proteins are often responsible for blood groups. The biological significance of these polymorphisms or the selective pressures responsible for their stability within populations are mostly not known, although exploitation of the proteins by pathogenic micro‐organisms has probably played a major role.
- 1 November 2007
- Published by Wiley in Vox Sanguinis
- Vol. 93 (4) , 331-340
Open AccessFunctions of red cell surface proteins
The external membrane of the red cell contains numerous proteins that either cross the lipid bilayer one or more times or are anchored to it through a lipid tail. Many of these proteins express blood group activity. The functions of some of these proteins are known; in others their function can only be surmised from the protein structure or from limited experimental evidence. They are loosely divided into four categories based on their functions: membrane transporters; adhesion molecules and receptors; enzymes; and structural proteins that link the membrane with the membrane skeleton. Some of the proteins carry out more than one of these functions. Some proteins may complete their major functions during erythropoiesis or may only be important under adverse physiological conditions. Furthermore, some might be evolutionary relics and may no longer have significant functions. Polymorphisms or rare changes in red cell surface proteins are often responsible for blood groups. The biological significance of these polymorphisms or the selective pressures responsible for their stability within populations are mostly not known, although exploitation of the proteins by pathogenic micro‐organisms has probably played a major role.
- 1 October 2007
- Published by Wiley in ISBT Science Series
- Vol. 2 (2) , 53-58
Red cell blood grouping in the molecular era
- 1 October 2007
- Published by Wiley in ISBT Science Series
- Vol. 2 (2) , 53-58
Red cell blood grouping in the molecular era
- 1 October 2007
- Published by Wiley in ISBT Science Series
- Vol. 2 (2) , 9-13
Red cell immunohaematology 2007
- 1 October 2007
- Published by Wiley in ISBT Science Series
- Vol. 2 (2) , 9-13
Red cell immunohaematology 2007
- 8 August 2007
- Published by Wiley in Transfusion
- Vol. 47 (11) , 2126-2133
Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell‐free fetal DNA in maternal plasma
BACKGROUND: When a pregnant woman has an antibody with the potential to cause hemolytic disease of the fetus and newborn, it is beneficial to determine whether her fetus has the corresponding antigen to assess risk. In many countries this is now done routinely for RhD, by testing cell‐free fetal DNA in the maternal plasma. Similar tests for K, C, c, and E are reported.STUDY DESIGN AND METHODS: Real‐time quantitative polymerase chain reaction incorporating an allele‐specific primer was developed for detecting the K allele of KEL and the C, c, and E alleles of RHCE. These methods were used to test DNA isolated from plasma of pregnant women with antibodies to K, C, c, or E. Accuracy of the tests was determined by comparing results with serologic tests performed on cord red blood cells (RBCs) after delivery or by molecular genotyping on DNA obtained from fetal cells.RESULTS: The K test incorporated an allele‐specific primer with two locked nucleic acids and a mismatch. In 70 tests, including 27 K+ fetuses, only one false‐negative and no false‐positive results were obtained. The C, c, and E tests, performed on 13, 44, and 46 samples, respectively, gave rise to no false results.CONCLUSION: Reliable methods have been developed for predicting fetal K, C, c, and E phenotypes, by testing fetal DNA in the plasma samples of pregnant women whose RBCs lack the corresponding antigens. These methods are now being used routinely in a diagnostic service in the United Kingdom.
- 8 August 2007
- Published by Wiley in Transfusion
- Vol. 47 (11) , 2126-2133
Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell‐free fetal DNA in maternal plasma
BACKGROUND: When a pregnant woman has an antibody with the potential to cause hemolytic disease of the fetus and newborn, it is beneficial to determine whether her fetus has the corresponding antigen to assess risk. In many countries this is now done routinely for RhD, by testing cell‐free fetal DNA in the maternal plasma. Similar tests for K, C, c, and E are reported.STUDY DESIGN AND METHODS: Real‐time quantitative polymerase chain reaction incorporating an allele‐specific primer was developed for detecting the K allele of KEL and the C, c, and E alleles of RHCE. These methods were used to test DNA isolated from plasma of pregnant women with antibodies to K, C, c, or E. Accuracy of the tests was determined by comparing results with serologic tests performed on cord red blood cells (RBCs) after delivery or by molecular genotyping on DNA obtained from fetal cells.RESULTS: The K test incorporated an allele‐specific primer with two locked nucleic acids and a mismatch. In 70 tests, including 27 K+ fetuses, only one false‐negative and no false‐positive results were obtained. The C, c, and E tests, performed on 13, 44, and 46 samples, respectively, gave rise to no false results.CONCLUSION: Reliable methods have been developed for predicting fetal K, C, c, and E phenotypes, by testing fetal DNA in the plasma samples of pregnant women whose RBCs lack the corresponding antigens. These methods are now being used routinely in a diagnostic service in the United Kingdom.
- 8 May 2007
- Published by Wiley in Vox Sanguinis
- Vol. 93 (1) , 83-88
Report of the Second International Workshop on molecular blood group genotyping
The second International Society of Blood Transfusion and International Council for Standardization in Haematology workshop on molecular blood group genotyping was held in 2006. Forty‐one laboratories participated. Six samples were distributed: two representing DNA from transfusion‐dependent patients for testing for all clinically important polymorphisms; two representing DNA from amniotic fluid for RhD, Rhc, and K testing; and two plasma samples from RhD‐negative pregnant women for fetal RhD testing (only tested by 20 laboratories). Overall, a high level of accuracy was achieved by most of the laboratories, although the error rate caused by RHDΨ was not acceptable and needs to be addressed. With greater care and attention to detail, very high standards could be set for molecular blood group genotyping.
- 8 May 2007
- Published by Wiley in Vox Sanguinis
- Vol. 93 (1) , 83-88
Report of the Second International Workshop on molecular blood group genotyping
The second International Society of Blood Transfusion and International Council for Standardization in Haematology workshop on molecular blood group genotyping was held in 2006. Forty‐one laboratories participated. Six samples were distributed: two representing DNA from transfusion‐dependent patients for testing for all clinically important polymorphisms; two representing DNA from amniotic fluid for RhD, Rhc, and K testing; and two plasma samples from RhD‐negative pregnant women for fetal RhD testing (only tested by 20 laboratories). Overall, a high level of accuracy was achieved by most of the laboratories, although the error rate caused by RHDΨ was not acceptable and needs to be addressed. With greater care and attention to detail, very high standards could be set for molecular blood group genotyping.